NCT01452828View on ClinicalTrials.gov

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Renal Impairment
Interventions
DRUG

TR-701 FA single infusion

Single IV infusion, 200 mg daily for 7 days

DRUG

TR-701 FA

Two separate infusions of 200 mg

DRUG

TR-701 FA

Single IV infusion, 200 mg daily for 7 days

Trial Locations (2)

32809

Trius Investigator Site 001, Orlando

55404

Trius Investigator Site 002, Minneapolis

All Listed Sponsors
lead

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01452828 - A Pharmacokinetics and Safety Study in Subjects With Renal Impairment | Biotech Hunter | Biotech Hunter